Cabaletta Bio Announces 2027 Rese-Cel BLA Submission Anticipated In Myositis Following Recent FDA Alignment On Registrational Cohorts
RefinitivOkuma süresi: 1 dakikadan kısa
Cabaletta Bio Inc 
CABA:
CABALETTA BIO ANNOUNCES 2027 RESE-CEL BLA SUBMISSION ANTICIPATED IN MYOSITIS FOLLOWING RECENT FDA ALIGNMENT ON REGISTRATIONAL COHORTS
CABALETTA BIO INC: SLE AND LN REGISTRATIONAL DISCUSSIONS WITH FDA ANTICIPATED IN 3Q25
CABALETTA BIO INC: SYSTEMIC SCLEROSIS REGISTRATIONAL DISCUSSIONS WITH FDA ANTICIPATED IN 4Q25
Bu haberi okumak için giriş yapın veya sonsuza kadar ücretsiz bir hesap oluşturun